drugset / Trial / NCT05628610
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the objective response rate (ORR) and safety of tislelizumab combined with chemotherapy and Tislelizumab combined with radiotherapy in elderly patients with esophageal cancer with advanced or recurrent metastasis
Timeline
- Start
- 2024-09-30
- Primary completion
- 2026-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Paclitaxel | Small molecule | 150 mg/m2 | — |
| Subject | naidaplatin | Unknown | — | — |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | — |